Dmitry Balyasny’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Dmitry Balyasny’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19.8M	Sell	309,682 -190,110	-38%	-$9.86M	0.02%	718
2026 Q1	$24.1M	Buy	+499,792	New	+$22.1M	0.03%	611
2025 Q2	–	Sell	-13,373	Closed	-$297K	–	3104
2025 Q1	$297K	Buy	13,373 +452	+3%	+$9.3K	﹤0.01%	2452
2024 Q4	$256K	Buy	+12,921	New	+$295K	﹤0.01%	2456
2024 Q2	–	Sell	-26,200	Closed	-$517K	–	2857
2024 Q1	$517K	Sell	26,200 -20,089	-43%	-$392K	﹤0.01%	2039
2023 Q4	$812K	Buy	+46,289	New	+$761K	﹤0.01%	1767
2023 Q1	–	Sell	-2,695	Closed	-$40.4K	–	2918
2022 Q4	$40.4K	Buy	+2,695	New	+$39.2K	﹤0.01%	2376
2021 Q3	–	Sell	-400,296	Closed	-$5.58M	–	2191
2021 Q2	$5.58M	Buy	+400,296	New	+$6.08M	0.03%	677

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Dmitry Balyasny's KNSA Position: Q2 2026 in Review

Dmitry Balyasny reduced its Kiniksa Pharmaceuticals (KNSA) stake by 38% in Q2 2026, selling an estimated $9.86M and leaving 309,682 shares worth $19.8M. The position accounts for 0.02% of the portfolio, ranked #718.

Dmitry Balyasny first reported a position in KNSA in Q2 2021 and has held it in 8 quarters since. The position peaked at $24.1M in Q1 2026. 265 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

Dmitry Balyasny held 309,682 shares of Kiniksa Pharmaceuticals worth $19.8M as of Q2 2026.
Dmitry Balyasny sold 190,110 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $9.86M.
Kiniksa Pharmaceuticals made up 0.02% of Dmitry Balyasny's portfolio in Q2 2026, its #718 holding.
Dmitry Balyasny first reported a position in Kiniksa Pharmaceuticals in Q2 2021 and has held it in 8 quarters since.
Dmitry Balyasny's Kiniksa Pharmaceuticals position peaked at $24.1M in Q1 2026.
265 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.